CHAMPS HF - We All Can do Better!

CHAMPS HF - We All Can do Better! Posted By:
...

Many of us manage patients with heart failure with a reduced ejection fraction, or HFrEF. The management of this patient population is complex, and most patients usually have more active problems than just heart failure. That is why it is not a surprise that a recent study showed that we as practitioners are not doing as well as we could when it comes to following the appropriate guidelines for heart failure.

According to the CHAMP-HF registry, many patients are not being prescribed the appropriate medications that are recommended within the guidelines published by the American Heart Association (AHA) and American College of Cardiology (ACC). The medications that were studied to determine their use and compliance with the guidelines were angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), beta blockers, angiotensin receptor/neprilysin inhibitors (ARNI), and mineralocorticoid receptor antagonists. The study showed a large percentage of eligible patients were either not placed on the appropriate medication, not given the target dose, or not prescribed medication at all. While ACE inhibitors and beta blockers were better than the other classes of medications, the data showed that there were significant gaps in coverage for medications that would benefit patients with heart failure. The conclusions were simple: patients who qualify for these medications should be placed on them when appropriate, and practitioners are encouraged to follow the AHA/ACC guidelines.

We all want our patients to succeed. However, following the recommended guidelines must be done in order to achieve the best possible outcomes for this complicated disease. We owe it to our patients to do better!

Reference
  • Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351-366.

Share

Filed under: Preventive Medicine , Cardiometabolic

Related
Phase III FLOW Trial Results Establishes Semaglutide’s Role in Treating T2D and CKD

Phase III FLOW Trial Results Establishes Semagluti ...

The highly anticipated results of the FLOW (Evaluate Renal Function with Semaglutide Once Weekly) tr ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
The Gift of Time and Key Connection Between Diabetes Mellitus and Autoimmune Disorders

The Gift of Time and Key Connection Between Diabet ...

Are you aware that approximately 64,000 Americans are diagnosed with type 1 diabetes (T1D) each year ...

Filed under: Cardiometabolic


Continue Reading
The Importance of Shared Decision-making in Obesity

The Importance of Shared Decision-making in Obesit ...

Many areas of healthcare are starting to talk about the importance of shared decision-making (SDM), ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Addressing ASCVD Risk in HIV: An Update to the DHHS HIV Guidelines

Addressing ASCVD Risk in HIV: An Update to the DHH ...

The incidence of atherosclerotic cardiovascular disease (ASCVD) is estimated to be twice as high in ...

Filed under: Infectious Diseases, Preventive Medicine, Public Health, Cardiometabolic, NPs & PAs


Continue Reading
Understanding the Multifactorial Etiology of Obesity and the Metabolic Adaptations to Weight Loss

Understanding the Multifactorial Etiology of Obesi ...

Obesity Causes Overeating, Not the Other Way AroundOne of my favorite quotes from Dr Lee Kaplan is, ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Atrial Fibrillation: Optimizing Outcomes by Addressing Social Determinants of Health and Implicit Bias

Atrial Fibrillation: Optimizing Outcomes by Addres ...

Atrial fibrillation (AF) is the most common sustained arrhythmia diagnosed, and its prevalence is ex ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading